Skip to main content
Marcel Nijland
dr.

I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.

European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Published in: The Lancet Haematology
Access to document 10.1016/S2352-3026(23)00030-3 document
Given the paucity of high-certainty evidence, and differences in opinion on the use of nuclear medicine for hematological malignancies, we embarked on a consensus process involving key experts in this area. We aimed to assess consensus within a panel of experts on issues related to patient eligibility, imaging techniques, staging and response assessment, follow-up, and treatment decision-making, and to provide interim guidance by our expert consensus. We used a three-stage consensus process. First, we systematically reviewed and appraised the quality of existing evidence. Second, we generated a list...
Cristina Nanni, Carsten Kobe, Bettina Baeßler, Christian Baues, Ronald Boellaard, Peter Borchmann, Andreas Buck, Irène Buvat, Björn Chapuy, Bruce D. Cheson, Robert Chrzan, Ann Segolene Cottereau, Ulrich Dührsen, Live Eikenes, Martin Hutchings, Wojciech Jurczak, Françoise Kraeber-Bodéré, Egesta Lopci, Stefano Luminari, Steven MacLennanN. George Mikhaeel, Marcel Nijland, Paula Rodríguez-Otero, Giorgio Treglia, Nadia Withofs, Elena Zamagni, Pier Luigi Zinzani, Josée M. Zijlstra, Ken Herrmann, Jolanta Kunikowska
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
Published in: Blood cancer journal
Access to document 10.1038/s41408-023-00854-2 document
Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP (R2CHOP) is well-tolerated and yields similar complete metabolic remission rates as more intensive chemotherapy regimens in literature. In parallel with this single-arm interventional trial, a prospective observational screening cohort (HOVON-900) was open in which we identified all newly diagnosed MYC-R DLBCL patients in the Netherlands. Eligible patients from the observational cohort that were not included in the interventional...
A. Vera de Jonge, Erik van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G.G.M. Rutten, Rogier Mous, Joost S.P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry Koene, Marie José Kersten, Daphne de Jong, Martine E.D. Chamuleau
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
Published in: Leukemia
Access to document 10.1038/s41375-022-01717-8 document
Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall...
HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC), Julia Driessen, Marie José Kersten, Lydia Visser, Anke van den Berg, Sanne H. Tonino, Josée M. Zijlstra, Pieternella J. Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J.C. Zwezerijnen, Ronald Boellaard, Henrica C.W. de Vet, Anne I.J. Arens, Roelf Valkema, Roberto D.K. Liu, Esther E.E. DreesDaphne de Jong, Wouter J. Plattel, Arjan Diepstra
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
Published in: Scientific Reports
Access to document 10.1038/s41598-022-10139-6 document
[177Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin’s lymphoma (NHL). Since patients are at risk for developing hematological toxicities due to CD37 expression on normal B cells, we aimed to develop 89Zr-labeled NNV003 for positron emission tomography (PET) imaging as a surrogate tool to predict [177Lu]Lu-DOTA-NNV003 RIT whole-body distribution and tumor uptake. NNV003 antibody was first radiolabeled with 89Zr. [89Zr]Zr-N-sucDf-NNV003 tumor uptake was evaluated by PET imaging of mice bearing human CD37-expressing REC1 B cell NHL or RAMOS...
Danique Giesen, Marjolijn N. Lub-de Hooge, Marcel Nijland, Helen Heyerdahl, Jostein Dahle, Elisabeth G.E. de Vries, Martin Pool
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness: During or After Chemotherapy
Published in: Jacc: cardiooncology
Access to document 10.1016/j.jaccao.2022.07.006 document
BACKGROUND: Despite the widely acknowledged benefit of exercise for patients with cancer, little evidence on the optimal timing of exercise on adverse effects of cancer treatment is available. OBJECTIVES: The aim of this study was to determine whether an exercise intervention initiated during chemotherapy is superior to an intervention initiated after chemotherapy for improving long-term cardiorespiratory fitness (peak oxygen uptake [VO 2peak]). METHODS: In this prospective, randomized clinical trial, patients scheduled to receive curative chemotherapy were randomized to a 24-week exercise intervention, initiated either during chemotherapy (group A)...
Gabriela G.F. van der Schoot, Harm L. Ormel, Nico-Derk L. Westerink, Anne M. May, Sjoerd G. Elias, Yoran M. Hummel, Joop D. Lefrandt, Peter van der Meer, Joost P. van Melle, Boelo J. Poppema, Joyce M.A. Stel, Annette W.G. van der Velden, Aline H. Vrieling, Johan B. Wempe, Marcel G. ten Wolde, Marcel Nijland, Elisabeth G.E. de Vries, Jourik A. Gietema, Annemiek M.E. Walenkamp